Suggested remit: To appraise the clinical and cost effectiveness of zanidatamab within its marketing authorisation for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Awaiting decision
- Process:
- STA Standard
- ID number:
- 6388
Provisional Schedule
- Committee meeting:
- 09 December 2025
- Expected publication:
- 14 May 2026
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Health Economics Research Unit and Health Services Research Unit, University of Aberdeen
Stakeholders
- Companies sponsors
- Jazz Pharmaceuticals
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- AMMF - The Cholangiocarcinoma Charity
- Professional groups
- Association of Cancer Physicians
- Cancer Research UK
- Royal College of Physicians
- Associated public health groups
- None
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- AS Kalceks (oxaliplatin) (confidentiality agreement not signed, not participating)
- Hospira (fluorouracil) (confidentiality agreement not signed, not participating)
- Medac (fluorouracil, folinic acid, oxaliplatin) (confidentiality agreement not signed, not participating)
- Ranbaxy (oxaliplatin) (confidentiality agreement not signed, not participating)
- Seacross Pharmaceuticals (oxaliplatin) (confidentiality agreement not signed, not participating)
- Relevant research groups
- Institute of Cancer Research 
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 May 2025 | Invitation to participate |
| 04 March 2025 - 01 April 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6388 |
| 04 March 2025 | In progress. Scoping commencing |
| 24 November 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 24 November 2023 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual